Target intelligence / Profile preview

Intestinal alkaline phosphatase (IAP) (IAP)

Target
IAP
Molecular classification
Enzyme, Hydrolase, Alkaline phosphatase family
01

Overview

Intestinal alkaline phosphatase (IAP) is a homodimeric metalloenzyme anchored to the brush-border membrane of the intestinal epithelium (UniProt Consortium, 2023). Its primary biological function involves the dephosphorylation of various phosphate esters, including pro-inflammatory molecules like lipopolysaccharides (LPS), flagellin, and extracellular adenosine triphosphate (ATP) (Lallès, 2010). By detoxifying these compounds at its catalytic site, IAP plays a pivotal role in maintaining the integrity of the intestinal barrier and preventing the translocation of bacteria and toxins into the systemic circulation (Malo et al., 2010). Reduced levels or activity of IAP are associated with chronic inflammatory conditions, such as inflammatory bowel disease and metabolic syndrome (Bilski et al., 2017). Therapeutic strategies often focus on supplementing IAP levels using bovine-derived or recombinant human enzymes to treat sepsis-associated acute kidney injury or to restore gut homeostasis (Pickkers et al., 2018). The enzyme's activity is also a key regulator of the gut microbiome and lipid absorption, making it a central player in metabolic health.

Other names
ALPIIntestinal-type alkaline phosphataseGlycerophosphataseKasahara isozyme
02

Mechanism of action

Hydrolysis of phosphate esters from pro-inflammatory substrates (e.g., LPS, ATP) at the catalytic site to reduce their toxicity and prevent systemic inflammation.

03

Biological functions

Dephosphorylation of lipopolysaccharides (LPS)Regulation of intestinal pHLipid absorptionMaintenance of gut microbiome homeostasisDetoxification of pro-inflammatory mediators
04

Disease associations

Inflammatory bowel diseaseSepsisAcute kidney injuryMetabolic syndromeType 2 diabetesNecrotizing enterocolitis
05

Safety considerations

Immunogenicity of non-human derived enzymesPotential for altering gut microbial balanceLimited systemic absorption when administered orally
06

Interacting drugs

Ilofotase alfa

3 more in the full profile.

07

Biomarkers

Fecal IAP activitySerum IAP levels

Beyond the preview

Go deeper on Intestinal alkaline phosphatase (IAP) (IAP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intestinal alkaline phosphatase (IAP) (IAP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call